Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain
ReviewHumans
- Design
- Review
- Subjects
- Narrative review
- Dose used in the study
- Not applicable
- Duration
- Not applicable
- What was measured
- Mechanisms (PPAR-alpha, mast cells, microglia, endocannabinoid interactions), pharmacokinetics and combination use in neurodegenerative disease models
What the authors reported
Experimental evidence, the authors say, shows palmitoylethanolamide reduces pain and inflammation and lowers the need for other drugs.
Limits of this study
A narrative review by authors outside the main Italian groups, with no pooled analysis. Its clinical claims rest on the trials already listed on this site. Authors declare no conflicts.
Source
PubMed 39714723 · doi:10.1007/s10787-024-01623-8
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.